Literature DB >> 32403954

Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy.

Claudio Marasca1, Angelo Ruggiero1, Matteo Megna1, Maria Carmela Annunziata1, Gabriella Fabbrocini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32403954     DOI： 10.1080/09546634.2020.1769828

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN： 0954-6634            Impact factor:   3.359


× No keyword cloud information.
  12 in total

Review 1.  The Impact of the SARS-CoV-2 Pandemic on Healthcare Provision in Italy to non-COVID Patients: a Systematic Review.

Authors:  Gianmarco Lugli; Matteo Maria Ottaviani; Annarita Botta; Guido Ascione; Alessandro Bruschi; Federico Cagnazzo; Lorenzo Zammarchi; Paola Romagnani; Tommaso Portaluri
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-01-01       Impact factor: 2.576

Review 2.  Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.

Authors:  Angelo Ruggiero; Luca Potestio; Elisa Camela; Gabriella Fabbrocini; Matteo Megna
Journal:  Psoriasis (Auckl)       Date:  2022-06-08

3.  Hidradenitis suppurativa and adalimumab in the COVID-19 era.

Authors:  Angelo Valerio Marzano; Chiara Moltrasio; Giovanni Genovese; Simona Muratori; Paolo Dapavo; Gabriella Fabbrocini; Annalisa Patrizi; Andrea Sechi; Giuseppe Micali; Michele Pellegrino; Paolo Gisondi; Valentina Dini; Luca Bianchi; Luca Fania; Annamaria Offidani; Francesca Prignano; Laura Atzori; Emanuele Miraglia; Serafinella Patrizia Cannavò; Vincenzo Bettoli; Luca Stingeni; Riccardo Balestri; Marina Venturini; Ketty Peris
Journal:  Eur J Dermatol       Date:  2020-12-01       Impact factor: 3.328

4.  Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.

Authors:  J Beecker; K A Papp; J Dutz; R B Vender; R Gniadecki; C Cooper; P Gisondi; M Gooderham; C H Hong; M G Kirchhof; C W Lynde; C Maari; Y Poulin; L Puig
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-02-03       Impact factor: 6.166

5.  Patterns and barriers of teledermatology in resource-limited settings in COVID-19 pandemic: A descriptive cross-sectional survey of Nepalese dermatologists.

Authors:  Vikash Paudel
Journal:  JAAD Int       Date:  2022-03-08

6.  Reply to "the significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea-like eruptions following COVID-19 vaccinations" by Ciccarese G. et al.

Authors:  Fabrizio Martora; Vincenzo Picone; Teresa Battista; Gabriella Fabbrocini; Claudio Marasca
Journal:  Dermatol Ther       Date:  2022-06-13       Impact factor: 3.858

Review 7.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16

8.  Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.

Authors:  Matteo Megna; Luca Potestio; Gabriella Fabbrocini; Angelo Ruggiero
Journal:  Psoriasis (Auckl)       Date:  2022-07-14

9.  Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns.

Authors:  Angelo Ruggiero; Matteo Megna; Gabriella Fabbrocini; Fabrizio Martora
Journal:  Clin Exp Dermatol       Date:  2022-06-03       Impact factor: 4.481

Review 10.  Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.

Authors:  Elia Rosi; Maria Thais Fastame; Antonella Di Cesare; Gianmarco Silvi; Nicola Pimpinelli; Francesca Prignano
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.